a:5:{s:8:"template";s:11935:"<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8">
<meta content="width=device-width, initial-scale=1" name="viewport">
<title>{{ keyword }}</title>
<style rel="stylesheet" type="text/css">@charset "UTF-8";.has-drop-cap:not(:focus):first-letter{float:left;font-size:8.4em;line-height:.68;font-weight:100;margin:.05em .1em 0 0;text-transform:uppercase;font-style:normal}.has-drop-cap:not(:focus):after{content:"";display:table;clear:both;padding-top:14px} html{line-height:1.15;-webkit-text-size-adjust:100%}*,:after,:before{-webkit-box-sizing:border-box;box-sizing:border-box}body{margin:0;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Helvetica Neue,Arial,Noto Sans,sans-serif;font-size:1rem;font-weight:400;line-height:1.5;color:#333;background-color:#fff}h3{margin-top:.5rem;margin-bottom:1rem;font-family:inherit;font-weight:500;line-height:1.2;color:inherit}h3{font-size:1.75rem}a{background-color:transparent;text-decoration:none;color:#c36}a:active,a:hover{color:#336}@media print{*,:after,:before{background:0 0!important;color:#000!important;-webkit-box-shadow:none!important;box-shadow:none!important;text-shadow:none!important}a,a:visited{text-decoration:underline}a[href]:after{content:" (" attr(href) ")"}h3{orphans:3;widows:3}h3{page-break-after:avoid}} .elementor-container{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;margin-right:auto;margin-left:auto;position:relative}.elementor-section.elementor-section-boxed>.elementor-container{max-width:1140px}.elementor-section.elementor-section-items-middle>.elementor-container{-webkit-box-align:center;-webkit-align-items:center;-ms-flex-align:center;align-items:center}.elementor-row{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex}@media (max-width:1024px){.elementor-row{-webkit-flex-wrap:wrap;-ms-flex-wrap:wrap;flex-wrap:wrap}}.elementor-column-wrap{width:100%;position:relative;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex}.elementor-widget-wrap{position:relative;width:100%;-webkit-flex-wrap:wrap;-ms-flex-wrap:wrap;flex-wrap:wrap;-webkit-align-content:flex-start;-ms-flex-line-pack:start;align-content:flex-start}.elementor:not(.elementor-bc-flex-widget) .elementor-widget-wrap{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex}.elementor-widget-wrap>.elementor-element{width:100%}.elementor-widget{position:relative}.elementor-column{position:relative;min-height:1px;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex}.elementor-column-gap-default>.elementor-row>.elementor-column>.e-e-populated{padding:10px}@media (min-width:768px){.elementor-column.elementor-col-25{width:25%}.elementor-column.elementor-col-33{width:33.333%}.elementor-column.elementor-col-50{width:50%}}@media (max-width:767px){.elementor-column{width:100%}}.elementor-element .elementor-widget-container{-webkit-transition:background .3s,border .3s,-webkit-border-radius .3s,-webkit-box-shadow .3s;transition:background .3s,border .3s,-webkit-border-radius .3s,-webkit-box-shadow .3s;-o-transition:background .3s,border .3s,border-radius .3s,box-shadow .3s;transition:background .3s,border .3s,border-radius .3s,box-shadow .3s;transition:background .3s,border .3s,border-radius .3s,box-shadow .3s,-webkit-border-radius .3s,-webkit-box-shadow .3s}.elementor-widget-heading .elementor-heading-title{padding:0;margin:0;line-height:1}.elementor-widget-image{text-align:center}/*! elementor-pro - v2.8.3 - 01-01-2020 */.swiper-slide:not(:hover)  .elementor-nav-menu{display:-webkit-box;display:-ms-flexbox;display:flex;-ms-flex-wrap:wrap;flex-wrap:wrap}.elementor-nav-menu--layout-horizontal .elementor-nav-menu a{white-space:nowrap}.elementor-nav-menu__align-right .elementor-nav-menu{margin-left:auto}.elementor-nav-menu__align-right .elementor-nav-menu{-webkit-box-pack:end;-ms-flex-pack:end;justify-content:flex-end}.elementor-widget-nav-menu .elementor-widget-container{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-ms-flex-direction:column;flex-direction:column}.elementor-nav-menu{position:relative;z-index:2}.elementor-nav-menu:after{content:"\00a0";display:block;height:0;font:0/0 serif;clear:both;visibility:hidden;overflow:hidden}.elementor-nav-menu,.elementor-nav-menu li{display:block;list-style:none;margin:0;padding:0;line-height:normal;-webkit-tap-highlight-color:transparent}.elementor-nav-menu a,.elementor-nav-menu li{position:relative}.elementor-nav-menu li{border-width:0}.elementor-nav-menu a{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-align:center;-ms-flex-align:center;align-items:center}.elementor-nav-menu a,.elementor-nav-menu a:focus,.elementor-nav-menu a:hover{padding:10px 20px;line-height:20px}@media (max-width:1024px){.elementor-nav-menu--dropdown-tablet .elementor-nav-menu--main{display:none}}.elementor-location-footer:before,.elementor-location-header:before{content:"";display:table;clear:both} .elementor-widget-heading .elementor-heading-title{color:#6ec1e4;font-family:Roboto,Sans-serif;font-weight:600}.elementor-widget-nav-menu .elementor-nav-menu .elementor-item{font-family:Roboto,Sans-serif;font-weight:600}.elementor-widget-nav-menu .elementor-nav-menu--main .elementor-item{color:#7a7a7a}.elementor-widget-nav-menu .elementor-nav-menu--main .elementor-item:focus,.elementor-widget-nav-menu .elementor-nav-menu--main .elementor-item:hover{color:#61ce70}.elementor-widget-nav-menu .elementor-nav-menu--main:not(.e--pointer-framed) .elementor-item:after,.elementor-widget-nav-menu .elementor-nav-menu--main:not(.e--pointer-framed) .elementor-item:before{background-color:#61ce70}.elementor-2965 .elementor-element.e-e-6faabd44>.elementor-container{min-height:80px}.elementor-2965 .elementor-element.e-e-6faabd44>.elementor-container:after{content:"";min-height:inherit}.elementor-2965 .elementor-element.e-e-6faabd44>.elementor-container>.elementor-row>.elementor-column>.elementor-column-wrap>.elementor-widget-wrap{align-content:center;align-items:center}.elementor-2965 .elementor-element.e-e-6faabd44:not(.elementor-motion-effects-element-type-background){background-color:#000}.elementor-2965 .elementor-element.e-e-6faabd44{transition:background .3s,border .3s,border-radius .3s,box-shadow .3s}.elementor-2965 .elementor-element.e-e-1355dad7 .elementor-nav-menu .elementor-item{font-family:Raleway,Sans-serif;font-size:15px;font-weight:400}.elementor-2965 .elementor-element.e-e-1355dad7 .elementor-nav-menu--main .elementor-item{color:#fff;padding-top:40px;padding-bottom:40px}.elementor-2965 .elementor-element.e-e-1355dad7 .elementor-nav-menu--main .elementor-item:focus,.elementor-2965 .elementor-element.e-e-1355dad7 .elementor-nav-menu--main .elementor-item:hover{color:#54595f}@media(min-width:768px){.elementor-2965 .elementor-element.e-e-66d36270{width:70.439%}}@media(max-width:1024px){.elementor-2965 .elementor-element.e-e-6faabd44{padding:30px 20px 30px 20px}}@media(max-width:767px){.elementor-2965 .elementor-element.e-e-6faabd44{padding:20px 20px 20px 20px}.elementor-2965 .elementor-element.e-e-799409b3{width:50%}.elementor-2965 .elementor-element.e-e-66d36270{width:35%}}.elementor-1908 .elementor-element.e-e-7eba06bb>.elementor-container{min-height:50px}.elementor-1908 .elementor-element.e-e-7eba06bb>.elementor-container:after{content:"";min-height:inherit}.elementor-1908 .elementor-element.e-e-7eba06bb>.elementor-container>.elementor-row>.elementor-column>.elementor-column-wrap>.elementor-widget-wrap{align-content:center;align-items:center}.elementor-1908 .elementor-element.e-e-7eba06bb:not(.elementor-motion-effects-element-type-background){background-color:#001c38}.elementor-1908 .elementor-element.e-e-7eba06bb{border-style:solid;border-width:1px 0 0 0;border-color:rgba(255,255,255,.19);transition:background .3s,border .3s,border-radius .3s,box-shadow .3s}.elementor-1908 .elementor-element.e-e-6d567ca1{text-align:left}.elementor-1908 .elementor-element.e-e-6d567ca1 .elementor-heading-title{color:#adadad;font-size:12px;font-weight:300}@media(max-width:1024px){.elementor-1908 .elementor-element.e-e-7eba06bb{padding:10px 20px 10px 20px}}@media(max-width:767px){.elementor-1908 .elementor-element.e-e-7eba06bb{padding:30px 20px 20px 20px}.elementor-1908 .elementor-element.e-e-1f4083b2>.e-e-populated{margin:0;padding:0}.elementor-1908 .elementor-element.e-e-6d567ca1{text-align:center}}</style>
</head>
<body class="wp-custom-logo unselectable">
<div class="elementor elementor-2965 elementor-location-header">
<div class="elementor-inner">
<div class="elementor-section-wrap">
<header class="elementor-element e-e-6faabd44 elementor-section-content-middle elementor-section-height-min-height elementor-section-boxed elementor-section-height-default elementor-section-items-middle elementor-section elementor-top-section">
<div class="elementor-container elementor-column-gap-no">
<div class="elementor-row">
<div class="elementor-element e-e-799409b3 elementor-column elementor-col-25 elementor-top-column">
<div class="elementor-column-wrap e-e-populated">
<div class="elementor-widget-wrap">
<div class="elementor-element e-e-5f7d36e7 elementor-widget elementor-widget-theme-site-logo elementor-widget-image">
<div class="elementor-widget-container">
<div class="elementor-image">
<h1>{{ keyword }}</h1>
</div>
</div>
</div>
</div>
</div>
</div>
<div class="elementor-element e-e-66d36270 elementor-column elementor-col-50 elementor-top-column">
<div class="elementor-column-wrap e-e-populated">
<div class="elementor-widget-wrap">
<div class="elementor-element e-e-1355dad7 elementor-nav-menu__align-right elementor-nav-menu--stretch elementor-nav-menu--indicator-classic elementor-nav-menu--dropdown-tablet elementor-nav-menu__text-align-aside elementor-nav-menu--toggle elementor-nav-menu--burger elementor-widget elementor-widget-nav-menu">
<div class="elementor-widget-container">
<nav class="elementor-nav-menu--main elementor-nav-menu__container elementor-nav-menu--layout-horizontal e--pointer-none" role="navigation"><ul class="elementor-nav-menu" id="menu-1-1355dad7"><li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-home menu-item-110"><a class="elementor-item" href="{{ KEYWORDBYINDEX-ANCHOR 0 }}">{{ KEYWORDBYINDEX 0 }}</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-109"><a class="elementor-item" href="{{ KEYWORDBYINDEX-ANCHOR 1 }}">{{ KEYWORDBYINDEX 1 }}</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-106"><a class="elementor-item" href="{{ KEYWORDBYINDEX-ANCHOR 2 }}">{{ KEYWORDBYINDEX 2 }}</a></li>
</ul></nav>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</header>
</div>
</div>
</div>
{{ text }}
<br>
{{ links }}
<div class="elementor elementor-1908 elementor-location-footer">
<div class="elementor-inner">
<div class="elementor-section-wrap">
<section class="elementor-element e-e-7eba06bb elementor-section-height-min-height elementor-section-content-middle elementor-section-boxed elementor-section-height-default elementor-section-items-middle elementor-section elementor-top-section" data-element_type="section" data-id="7eba06bb" data-settings='{"background_background":"classic"}'>
<div class="elementor-container elementor-column-gap-default">
<div class="elementor-row">
<div class="elementor-element e-e-1f4083b2 elementor-column elementor-col-33 elementor-top-column" data-element_type="column" data-id="1f4083b2">
<div class="elementor-column-wrap e-e-populated">
<div class="elementor-widget-wrap">
<div class="elementor-element e-e-6d567ca1 elementor-widget elementor-widget-heading">
<div class="elementor-widget-container">
<h3 class="elementor-heading-title elementor-size-default">{{ keyword }}</h3> </div>
</div>
</div>
</div>
</div>
</div>
</div>
</section>
</div>
</div>
</div>
</body>
</html>";s:4:"text";s:14266:"Vertex to get new investment from Cystic Fibrosis Foundation. CFF Therapeutics owned rights to any Vertex-developed CF treatments, but the foundation has deemed it more beneficial to … This money is now being reinvested in universities, biotech companies and large pharmaceutical companies to drive additional research into cystic fibrosis. The agreement includes an … It acquired the rights to those royalties from the Cystic Fibrosis Foundation. The agreement includes an upfront payment of $575 million and a potential … The agreement includes an upfront payment of $575 million and a potential milestone payment … The Cystic Fibrosis Foundation (CFF) has sold its royalty rights for cystic fibrosis drugs developed at Vertex Pharmaceuticals for $3.3 billion. The Cystic Fibrosis Foundation sold its royalty rights in several drugs to Royalty Pharma for $3.3 billion a few years ago, a milestone transaction for a charitable foundation. NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2021 and raised full-year 2021 guidance for Adjusted Cash Receipts(1) (a non-GAAP financial measure). Royalty Pharma, a leading investor in pre-approval royalties, in its $827 million acquisition of Ligand’s royalties on sales of Promacta Royalty Pharma in its up to $650 million acquisition of Vertex’s residual royalty interest in its cystic fibrosis … Royalty Pharma plc closed its agreement to acquire the residual royalty interest in Vertex Pharmaceuticals, Inc.’s cystic fibrosis treatments owned by the Cystic Fibrosis Foundation. The agreement includes an upfront payment of $575 million and a potential milestone payment of $75 million. December 7, 2014; NBC Philadelphia Last week, Scientific American revealed that the Cystic Fibrosis Foundation recently had a financial windfall through the sale of its royalty rights to a breakthrough drug for those suffering from the disease. (Reuters) - Pharmaceutical investment firm Royalty Pharma said it would buy royalties on Vertex Pharmaceuticals Inc's cystic fibrosis treatments from Cystic Fibrosis Foundation for $3.3 billion in cash. Bydivesting itself of its royalty stake in commercial products, CFFT sought to immediately capitalize on the availability of On Slide 11, I want to highlight our most recent transaction wherein we acquired the residual royalty interest of the Cystic Fibrosis Foundation in Vertex's CF franchise. So in exchange for a $575 million upfront payment and a potential $75 million milestone, Royalty Pharma will receive all Date of Report (Date of earliest event reported): October 30, 2020 So in exchange for a $575 million upfront payment and a potential $75 million milestone, Royalty Pharma will receive all Cystic Fibrosis Foundation changes the pharmaceutical industry. Royalty Pharma will pay $575 million in the deal and could shell out an additional $75 million in milestone payments. Approved drugs from Vertex, a Boston biotech, can treat around 90% of cystic fibrosis patients. This action is possible as a result of the sale of the Foundation's royalty rights to CF treatments developed by … The agreement includes an upfront payment of $575 million and a potential milestone payment of $75 million. In 2014, the Cystic Fibrosis Foundation announced an injection of funds so large that it increased the organisation’s cash budget 18-fold. “We are honored to work with the Cystic Fibrosis Foundation on this extraordinary royalty transaction, says Pablo Legorreta, Royalty Pharma’s Chief Executive Officer, who founded Royalty Pharma in 1996, after creating and managing two “proof of principle” investment vehicles in 1993 and 1994 that invested in royalty interests in two leading biotechnology products. The payment is … This money is now being reinvested in universities, biotech companies and large pharmaceutical companies to drive additional research into cystic fibrosis. 1. Through its venture philanthropy model, the Cystic Fibrosis Foundation provides early stage funding to biotechnology and pharmaceutical companies to develop breakthrough drugs for cystic fibrosis. Through its venture philanthropy model, the Cystic Fibrosis Foundation provides early stage funding to biotechnology and pharmaceutical companies to develop breakthrough drugs for cystic fibrosis. Approved by the FDA in 2012, Kalydeco is the first drug that treats the root cause of the devastating disease Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement to acquire the residual royalty interest in Vertex Pharmaceuticals, Inc.’s cystic fibrosis (CF) treatments owned by the Cystic Fibrosis Foundation. The Cystic Fibrosis Foundation today announced an unprecedented acceleration and expansion of its research, care and patient programs for the CF community. The Life Sciences team advised Royalty Pharma plc (Nasdaq: RPRX) on the acquisition of the residual royalty interest in Vertex Pharmaceuticals, Inc.’s cystic fibrosis (CF) treatments owned by the Cystic Fibrosis Foundation. November 24, 2014. NEW YORK, NY, November 2, 2020 - Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement to acquire the residual royalty interest in Vertex Pharmaceuticals, Inc.’s cystic fibrosis (CF) treatments owned by the Cystic Fibrosis Foundation. Researchers are investigating potential therapies to restore proper function to the CFTR protein or correct its production process so that a normal protein is made. The journey to end cystic fibrosis isn't a straight line. It is an evolving map with many paths and unique challenges. Royalty Pharma founder & chief executive officer Pablo Legorreta launched the company back in 1996. Legorreta is a former investment banker and he is known for pioneering the concept around generating royalties from pharmaceuticals. The company originally launched in the form of a private equity firm that acquired royalties of drugs. The Cystic Fibrosis Foundation will sell royalties it gets from Vertex Pharmaceuticals Inc. for $3.3 billion to Royalty Pharma, taking a profit … Royalty Pharma Acquires Additional Royalty Interest From the Cystic Fibrosis Foundation. Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement to acquire the residual royalty interest in Vertex Pharmaceuticals, Inc.’s cystic fibrosis (CF) treatments owned by the Cystic Fibrosis Foundation. Tysabri: Royalty Pharma: Perrigo: 2,850: Mar 2017: Perrigo was owed royalties on sales from Biogen; deal comprised $2.2bn cash, plus $650m dependent on sales thresholds. Kalydeco, which costs more than $300,000 a year, helps cystic fibrosis patients with a rare genetic mutation, according to Robert Beall, president of the Cystic Fibrosis Foundation (CFF). Royalty Pharma’s $3.3 billion deal with the Cystic Fibrosis Foundation to purchase royalties on Vertex’s CF franchise was its largest royalty deal ever. Royalty Pharma, a leading investor in pre-approval royalties, in its $827 million acquisition of Ligand’s royalties on sales of Promacta Royalty Pharma in its up to $650 million acquisition of Vertex’s residual royalty interest in its cystic fibrosis … In 2014, the CF Foundation sold rights to royalties related to those therapies to a third-party group called Royalty Pharma. For example, in 2014 the Cystic Fibrosis Foundation sold Royalty Pharma a share of the royalties for cystic fibrosis treatments developed by Vertex Pharmaceuticals (NASDAQ:VRTX) for $3.3 billion. In 2014, the Cystic Fibrosis Foundation sold Royalty Pharma sold a portion of the royalties for cystic fibrosis treatments that were developed by Vertex Pharmaceuticals for $3.3 billion, according to The Motley Fool. Founded in 1996, Royalty … Under terms of the agreement with Royalty Pharma, it is possible the Foundation may receive additional funds in future years. Royalty Pharma Acquires Additional Royalty Interest From the Cystic Fibrosis Foundation. Engaging with biotechnology and pharmaceutical companies and other … In 2014, the CF Foundation sold rights to royalties related to those therapies to a third-party group called Royalty Pharma. Pharmaceutical investment firm Royalty Pharma said it would buy royalties on Vertex Pharmaceuticals Inc's cystic fibrosis treatments from … The proceeds of the sale will dramatically accelerate and expand the foundation’s research, care, and patient programs and significantly boost its funding of … Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement to acquire the residual royalty interest in Vertex Pharmaceuticals, Inc.’s cystic fibrosis (CF) treatments owned by the Cystic Fibrosis Foundation. “We are honored to work with the Cystic Fibrosis Foundation on … In 2014, the Cystic Fibrosis Foundation sold Royalty Pharma sold a portion of the royalties for cystic fibrosis treatments that were developed by Vertex Pharmaceuticals for $3.3 billion, according to The Motley Fool. And the first-quarter sales Vertex’s cystic fibrosis drugs jumped 77% year over year to an annualized $6.1 billion. Nov 2, 2020 7:30AM EST. But that didn’t buy it … At that time, there were no approved treatments for CF, and no research was being conducted on the disease Over the years, the CFF has . In 2014, it agreed to pay $3.3 billion to an affiliate of the Cystic Fibrosis Foundation for rights to the drug Kalydeco and other treatments for cystic fibrosis marketed by Vertex Pharmaceuticals. Readers of my Near Future Report know Vertex well. This takes its addressable market up from 50% to 90% of the cystic fibrosis population. In 2014 Royalty Pharma acquired the royalty stream promised to the Cystic Fibrosis Foundation by Vertex Pharmaceuticals on sales of the drug, Kalydeco, for $3.3 billion; the CFF had invested in discovery and development of the drug under the venture philanthropy model, and said it intended to use proceeds from the royalty sale to further invest in treatments for cystic fibrosis. NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2021 and raised full-year 2021 guidance for Adjusted Cash Receipts(1) (a non-GAAP financial measure). The transaction is by far the largest undertaken by the drug financing firm. This is the company that partnered with CRISPR Therapeutics (CRSP) on its lead CRISPR genetic editing therapy. Royalty Pharma Acquires Additional Royalty Interest From the Cystic Fibrosis Foundation. The agreement includes an upfront payment of $575 million and a potential milestone payment … History of the Cystic Fibrosis Foundation The Cystic Fibrosis Foundation, currently based in Bethesda, Maryland, was founded in 1955 by parents of children with CF. New York-based Royalty Pharma, which buys up royalty interests in marketed and late stage biopharmaceutical products, is making the $3.3 billion cash … NEW YORK, Nov. 02, 2020 -- Royalty Pharma plc announced today an agreement to acquire the residual royalty interest in Vertex Pharmaceuticals, Inc.’s cystic fibrosis treatments owned... | October 18, 2021 Mintz advised the Cystic Fibrosis (CF) Foundation, a donor-supported nonprofit leading the global search for a cure for CF, in the sale of its residual royalty interest in Vertex Pharmaceuticals, Inc. (Vertex)’s CF treatments to Royalty Pharma plc (Nasdaq: RPRX). Kalydeco treats a variant of the disease covering … The Cystic Fibrosis (CF) Foundation has sold royalty rights to treatments developed with support from its ‘venture philantrophy’ model. The agreement includes an upfront payment of $575 million and a potential milestone payment of $75 million. This action is possible as a result of the sale of the Foundation's royalty rights to CF treatments developed by … The Foundation sold the rights to Royalty Pharma for $3.3 billion. With a new unprecedented level of resource, the ripple effect on the broader CF treatment space spanned stakeholders from research communities and patient groups to pharmaceutical companies undertaking R&D. Fifteen years later, Royalty Pharma upped its game in the CF market, acquiring the Cystic Fibrosis Foundation's royalties on sales of CF … ... New York–based investment firm … The Cystic Fibrosis Foundation said Wednesday that it would receive $3.3 billion for the sale of royalty rights to drugs developed with its financial support. In the deal, the largest ever of its kind, Royalty Pharma will pay the foundation $3.3 billion for its share of revenue from the sale of cystic fibrosis drugs developed by Vertex Pharmaceuticals. In fact, Royalty Pharma worked out a great deal with the Cystic Fibrosis Foundation that enabled it to benefit from the success of Vertex Pharmaceuticals (VRTX). The $3.3 billion paid by Royalty Pharma to the Cystic Fibrosis Foundation to acquire royalty rights to Vertex Pharmaceuticals' cystic fibrosis drugs suggests investors are under-estimating peak sales. Longtime Goodwin client Royalty Pharma, a global leader in life sciences financing, was seeking to enter into a historic agreement with the Cystic Fibrosis Foundation that would secure royalties for a promising drug while delivering a significant windfall for the foundation to expand research. Royalty Pharma, a company dedicated to acquiring royalty interests in marketed and late stage biopharmaceutical products, announced today that it has acquired royalties on Vertex Pharmaceuticals ’ cystic fibrosis treatments for $3.3 billion. On November 19, 2014, the Cystic Fibrosis Foundation (CFF), a charity, received its biggest paycheck ever, for $3.3 billion. The mission of the Cystic Fibrosis Foundation (CF Foundation) is to cure cystic fibrosis and to provide all people with cystic fibrosis the opportunity to lead long, fulfilling lives by funding research and drug development, partnering with the CF community, and advancing high-quality, specialized care. The Cystic Fibrosis Foundation today announced the sale of future royalty rights to Royalty Pharma, bringing in an amount that's more than the nonprofit's total revenues last year. ";s:7:"keyword";s:42:"cystic fibrosis foundation, royalty pharma";s:5:"links";s:1597:"<a href="http://suam.cucsh.udg.mx/inscripciones2020b/storage/o0j5u6/john-schneider-seahawks-son.html">John Schneider Seahawks Son</a>,
<a href="http://suam.cucsh.udg.mx/inscripciones2020b/storage/o0j5u6/affordable-flooring-installation-near-me.html">Affordable Flooring Installation Near Me</a>,
<a href="http://suam.cucsh.udg.mx/inscripciones2020b/storage/o0j5u6/mustard-dipping-sauce.html">Mustard Dipping Sauce</a>,
<a href="http://suam.cucsh.udg.mx/inscripciones2020b/storage/o0j5u6/griffin-luce-michigan.html">Griffin Luce Michigan</a>,
<a href="http://suam.cucsh.udg.mx/inscripciones2020b/storage/o0j5u6/wright-%26-ford-funeral-home-obituaries.html">Wright & Ford Funeral Home Obituaries</a>,
<a href="http://suam.cucsh.udg.mx/inscripciones2020b/storage/o0j5u6/is-couran-cove-still-operating.html">Is Couran Cove Still Operating</a>,
<a href="http://suam.cucsh.udg.mx/inscripciones2020b/storage/o0j5u6/motor-vehicle-accident-report.html">Motor Vehicle Accident Report</a>,
<a href="http://suam.cucsh.udg.mx/inscripciones2020b/storage/o0j5u6/baum-und-pferdgarten-wiki.html">Baum Und Pferdgarten Wiki</a>,
<a href="http://suam.cucsh.udg.mx/inscripciones2020b/storage/o0j5u6/staphylococcus-aureus-topical-treatment.html">Staphylococcus Aureus Topical Treatment</a>,
<a href="http://suam.cucsh.udg.mx/inscripciones2020b/storage/o0j5u6/creative-description-of-an-office.html">Creative Description Of An Office</a>,
<a href="http://suam.cucsh.udg.mx/inscripciones2020b/storage/o0j5u6/difference-between-widman-and-modified-widman-flap.html">Difference Between Widman And Modified Widman Flap</a>,
";s:7:"expired";i:-1;}